Abatacept for the Treatment of Giant Cell Arteritis
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy
of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed
or relapsing GCA within 8 weeks prior to screening will be randomized at a 1:1 ratio to
receive subcutaneous abatacept 125mg/week or placebo. Patients who achieve remission will
remain on their blinded assignment for 12 months at which time abatacept/placebo will be
stopped.
Patients who do not achieve remission by Month 3, who experience a relapse within the first
12 months will have the option of receiving open-label abatacept for a maximum of 12 months.